AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02993458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Diet
Description: The usual diet will include foods that provide the majority of energy for adolescents in the U.S., i.e. grain based desserts, pizza, sugary drinks,pasta, chicken, and chicken mixed dishes.
Study NCT01017887 — intervention group
Intervention type: DEVICE
Intervention: Airseal access port for laparoscopic surgery
Description: The investigators will utilize this access port that is already approved by the FDA for it's intended use in laparoscopic surgery. The investigators are simply measuring the percentage of carbon dioxide in the peritoneal cavity.
Study NCT01017887 — intervention group
Intervention type: DEVICE
Intervention: Standard Laparoscopy ports
Description: Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.
Study NCT00966693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT00966693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT00966693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given PO
Study NCT01928992 — intervention group
Intervention type: DEVICE
Intervention: 3D
Description: subjects that underwent 3D mammography
Study NCT01928992 — intervention group
Intervention type: DEVICE
Intervention: 2D
Description: those subjects that underwent 2D mammography
Study NCT01714011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole and to a lesser extent, to its major metabolite, dehyrdro-aripiprazole. Steady state concentrations are attained with in 14 days of dosing. The mean elimination half lives are about 75 hours and 95 hours respectively. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Absorption of aripiprazole is not affected by food.
Study NCT02695225 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lay-led tobacco abstinence
Description: Lay-led tobacco abstinence: Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
Study NCT02695225 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lay-led promotion of Ohio Quit Line
Description: Lay-led promotion of Ohio Quit Line (control condition): Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
Study NCT03089970 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exhaled breath condensate collection
Description: Breath from humans is cooled, condensed, and collected
Study NCT02575144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
Study NCT04344184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-ascorbic acid
Description: 50 mg/kg intravenous vitamin C infusion every 6 hours for up to 96 hours
Study NCT03556748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole-body electromyostimulation
Description: WB-EMS training is performed 2x/week for a total of 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
Study NCT00002718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT00002718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00002718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00002718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00002718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study NCT00002718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Study NCT00002718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated bone marrow transplantation
Study NCT00002718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation
Study NCT00002718 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01292044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastography
Description: A conventional thyroid echography performed before a the time of fine needle aspiration will include elastographic measurements for each node under study.
Study NCT00795509 — intervention group
Intervention type: DRUG
Intervention: Tolterodine tartrate
Description: Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability.
Study NCT02282176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin IV 10mg/kg daily for 10 days
Study NCT02282176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Azithromycin placebo (5% Dextrose) daily for 10 days
Study NCT02146833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Comparison of different dosages and dosing schedules of drug.
Study NCT02013089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib or Gefitinib
Description: Erlotinib 150mg talbet or Gefitinib 250 mg tablet per day for patients with EGFR gene alternation
Study NCT02013089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10 mg orally once daily every day for patients with mTOR gene alternation
Study NCT02013089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400 mg tablet orally per day for patietns with KIT, PDGFR, ABL gene alternation
Study NCT02013089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib or Sunitinib
Description: Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day with or without food for patients with VEGFR, KIT, RAF gene alternation
Study NCT02013089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Vandetanib 300 mg orally once daily for patients with RET gene fusion.
Study NCT05221788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic therapy
Description: Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If SV increased >10%, 200 ml of electrolyte solution was continued until SV increased \<10%. After fluid shock, if SV increases \<10% but mean arterial pressure (MAP) \<65 mmHg and/or cardiac index (CI) \<2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output \<0.5 ml /kg/h and/or heart rate more than 20% above baseline), plasma was administered until urine output and/or HR returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
Study NCT02356640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided celiac ganglion neurolysis
Description: EUS-CGN would be performed with a linear video echoendoscope (Olympus UM 2000; Olympus Co Ltd, Japan). The celiac ganglia are visualized under linear EUS and the injection would be applied directly into the ganglia. It is represented by small 2 to 3 mm hypoechoic nodules with hyperechoic foci in the center or a single elongated hypoechoic structure. IIf the ganglia are not identified by EUS, then injection would be performed as bilateral injections at the celiac vessel trunk. All procedures would be performed by a two experienced endosonographer.
Study NCT02356640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous celiac plexus neurolysis
Description: Percutaneous fluoroscopy-guided CPN would be performed in the operation theatre with the transcural technique. A 22-gauge, 17 cm-long spinal needle (B-D Quincke Type Point, Becton Dickinson \&Co., NJ 07417, USA) would be inserted and advanced just caudal to the margin of 12th rib and cephalad to the transverse process of L1 toward the anterolateral surface of the L1 vertebral body. Final needle position would be confirmed by radiographic contrast, layering over anterior surface of aorta. 10mL of levobupivacaine (0.25%), followed by 10mL of absolute alcohol would be injected on both sides using separate punctures.
Study NCT02356640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Olympus UM 2000
Study NCT02356640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B-D Quincke Type Point
Study NCT02356640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Study NCT04045626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corneal cross-linking
Description: Riboflavin is instilled over cornea followed by Ultraviolet-A irradiation
Study NCT02079558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Carbetocin with single 100 microg IV dosage was used in this investigation
Study NCT02079558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin with 30 international units (IU) IV infusion was used in this investigation
Study NCT03225937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab, Lapatinib
Description: Patients enrolled in Cohort A will receive lapatinib 1000 mg daily per os + trastuzumab 4 mg/kg iv load, followed by 2 mg/kg iv weekly. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.
Study NCT03225937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab-emtansine
Description: Patients enrolled in Cohort B will receive pertuzumab 840 mg iv load, followed by 420 mg iv Q3weeks + trastuzumab-emtansine 3.6 mg/kg iv on day 1 of each subsequent 3 week cycle.~Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.
Study NCT01928563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine
Study NCT01928563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Study NCT04344184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose 5% Water
Study NCT01928563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil+Dapoxetine
Study NCT02030821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amicar
Description: Subjects randomized to receive Amicar will receive this during surgical intervention
Study NCT02030821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TXA
Description: Subjects randomized to receive TXA will receive this during surgical intervention
Study NCT04861714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regeneten
Description: Augmentation of standard subscapularis repair with regeneten patch
Study NCT04861714 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard repair
Description: Standard subscapularis repair
Study NCT02153489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Study NCT02153489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01060254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 12 wks
Study NCT01060254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use. One injection of 9 mg of JNJ-42160443 every 28 days for up to 12 wks
Study NCT03822507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580
Description: oral administration
Study NCT03822507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet Hydrochloride
Description: oral administration
Study NCT00127036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: XELOX: Oxaliplatin 130 mg/m\^2 intravenously (IV); Capecitabine 825 mg/m\^2 by mouth (po)
Study NCT00127036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELIRI
Description: XELIRI: Irinotecan 240 mg/m\^2 IV; Capecitabine 825 mg/m\^2 by mouth (po)
Study NCT00127036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg intravenously (IV)
Study NCT01855074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
Study NCT01432418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair skills training program
Description: A training program that uses methods based on the rehabilitation, wheelchair, and motor skills literature to teach wheelchair skills.
Study NCT02651454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daesiho-tang
Description: Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study NCT02651454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chowiseungcheng-tang
Description: Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
Study NCT02651454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study NCT00872885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6005
Description: liquid formulation, 200 to 600 µg, single dose, one day
Study NCT00872885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 60 mg
Study NCT00872885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dosage
Study NCT00031499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Single 2 gram oral dose (4 tablets) at Day 1.
Study NCT00031499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzathine Penicillin
Description: Supplied in pre-filled syringes containing 1.2 million units of benzathine penicillin; 2.4 million units administered intramuscularly at Day 1, in one or both buttocks.
Study NCT00031499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Baseline visit, 28 capsules dispensed, for a dose of 100 mg twice a day (BID).
Study NCT00377429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catumaxomab
Description: Catumaxomab administered as four 3-hour, constant-rate, intraperitoneal (IP) infusions of 10, 20, 50, 150 microgram (mcg).
Study NCT03258697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine Hydrochloride
Description: Different way of LevoBupivacaine injection
Study NCT03258697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride
Description: Different way of LevoBupivacaine injection
Study NCT02190617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Clinic+ Unified Plan + CHW
Description: * Unified asthma management plan and asthma support team coordination: A support team will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan.~* Home visit intervention: Community health workers will provide in-home tailored asthma support and conduct follow-up to support patient actions to improve asthma control based on unified asthma management plan.~* Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign.
Study NCT02190617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Clinic+ Unified Management Plan
Description: * Unified asthma management plan and asthma support team coordination: A support team (clinicians, CHWs and plan care managers) will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan and enhancing communications among care team.~* Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign.
Study NCT02190617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHW Home Visit Only
Description: -Home visit intervention: Community health workers will provide in-home tailored asthma support: assess asthma self-management knowledge and skills, conduct a home environmental assessment focused on asthma triggers, and conduct follow-up visits to support patient actions to improve asthma control based on unified asthma management plan.
Study NCT00602277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00602277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wild-type Reovirus
Study NCT01648829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Patients will receive randomly atorvastatin (20 mg day) for 30 days
Study NCT01648829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: Patients will receive randomly pitavastatin (4 mg day) for 30 days
Study NCT04029987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Ultrasound-Guided Transmuscular Quadratus Lumborum Block.
Description: A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoa Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
Study NCT04029987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Ultrasound-Guided intra smuscular Quadratus Lumborum Block.
Description: A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
Study NCT04029987 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Conventional analgesia
Study NCT02058082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracytoplasmic sperm injection
Study NCT01261975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coaxial Micro-Incision Cataract Surgery
Description: 1.8 mm coaxial micro incision
Study NCT01261975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coaxial Small Incision Cataract Surgery
Description: 2.75 mm coaxial incision
Study NCT01722929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Skin sensor
Study NCT01722929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin sensor
Study NCT01642303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vodcasting
Description: listening to downloaded vodcasting files